Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0079731 (
B-cell lymphoma
)
16,671
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CD300A
is a type I transmembrane receptor protein which has shown inhibitory effects on B-cell receptor-mediated signals. In an analysis of public dataset, we found that
CD300A
mRNA levels were inversely correlated with the overall survival time of patients with diffuse large
B-cell lymphoma
(DLBCL). To decipher the role of
CD300A
in DLBCL, we knocked down the expression levels of
CD300A
in DLBCL cells and found that decreasing levels of
CD300A
significantly inhibited cell proliferation of OCI-Ly01, Farage, and SUDHL-4 cells, but not of VAL, OCI-Ly10, or SUDHL-8 cells. Mechanistically, reduced expression of
CD300A
resulted in a marked attenuation of AKT phosphorylation, a key molecular event in tumorigenesis, in OCI-Ly01, Farage, and SUDHL-4 cells. Pharmacologic inhibition of PI3K displayed a similar inhibitory effect on cell proliferation. Furthermore, using a xenograft animal model, we found that decreasing levels of
CD300A
in OCI-Ly01 and Farage cells significantly inhibited tumor formation in vivo. Collectively, our results suggested an oncogenic role of
CD300A
in DLBCL which could serve as a potential biomarker and therapeutic target for this malignant disease.
...
PMID:Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma. 2849 31
